• Nektar Therapeutics granted inducement equity awards on April 20, 2026 to six newly hired employees under its 2025 Inducement Plan.
• Awards comprised non-qualified stock options covering 28,450 shares plus 2,950 restricted stock units.
• Options carry an exercise price of $100.35 per share.
• Option term set at eight years.
• Equity awards vest over four years, subject to continued employment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605011639PR_NEWS_USPR_____SF49249) on May 01, 2026, and is solely responsible for the information contained therein.